BTG plc (BTG) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of BTG plc (LON:BTG) have received a consensus recommendation of “Buy” from the nine ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is GBX 777.57 ($10.47).

Several research analysts have commented on the stock. J P Morgan Chase & Co reissued a “neutral” rating on shares of BTG in a report on Friday. Numis Securities restated a “buy” rating and set a GBX 900 ($12.11) price objective on shares of BTG in a research report on Friday. Deutsche Bank restated a “buy” rating and set a GBX 775 ($10.43) price objective on shares of BTG in a research report on Thursday, September 21st. Peel Hunt restated a “hold” rating and set a GBX 680 ($9.15) price objective on shares of BTG in a research report on Wednesday, September 20th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a GBX 800 ($10.77) target price on shares of BTG in a research report on Wednesday, August 30th.

Shares of BTG (BTG) opened at GBX 733.50 ($9.87) on Monday. BTG has a fifty-two week low of GBX 528.36 ($7.11) and a fifty-two week high of GBX 779 ($10.48).

BTG (LON:BTG) last posted its quarterly earnings data on Tuesday, November 14th. The company reported GBX 21 ($0.28) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of GBX 21 ($0.28). BTG had a net margin of 15.50% and a return on equity of 10.80%. The firm had revenue of £341.30 million during the quarter.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this piece of content can be accessed at

About BTG

BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.

Analyst Recommendations for BTG (LON:BTG)

Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with's FREE daily email newsletter.

Leave a Reply